STOCK TITAN

Armistice Capital, Steven Boyd report 9.99% stake in ADIL (NASDAQ: ADIL)

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

ADIAL PHARMACEUTICALS ownership disclosure: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 2,799,643 shares, representing 9.99% of common stock as of 12/31/2025. Armistice is the investment manager of Armistice Capital Master Fund Ltd., the direct holder; the Master Fund is listed as having the right to receive dividends or sale proceeds. The filing states voting and dispositive power over the shares is held jointly (shared power: 2,799,643), and the share counts are based on information from the issuer.

Positive

  • None.

Negative

  • None.

Insights

Armistice reports a near-10% stake held via its Master Fund with shared voting and dispositive power.

Armistice Capital, as investment manager, and Steven Boyd, as managing member, report beneficial ownership of 2,799,643 shares (9.99%) as of 12/31/2025. The filing states these figures are "based on information from the Issuer."

The Master Fund is identified as the direct holder and "has the right to receive dividends from, or the proceeds from the sale of, the reported securities." Timing and any plans for disposition are not disclosed in the provided excerpt.

This is a routine beneficial ownership schedule showing a single institutional holder near the 10% threshold.

The report lists shared voting and dispositive power of 2,799,643 shares and states the percentage (9.99%). The Master Fund specifically disclaims beneficial ownership by virtue of its Investment Management Agreement with Armistice Capital.

Material impact depends on future disclosures or transactions by the holder; the filing itself records ownership without describing transactions or timing.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Armistice Capital, LLC
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd - Managing Member
Date:02/17/2026
Steven Boyd
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd
Date:02/17/2026
Exhibit Information

JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: February 17, 2026 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd

FAQ

What stake does Armistice Capital hold in ADIL?

Armistice Capital reports beneficial ownership of 2,799,643 shares, equal to 9.99% of ADIL common stock as of 12/31/2025. The figure is reported based on information provided by the issuer.

Who is the direct holder of the ADIL shares reported?

The direct holder is Armistice Capital Master Fund Ltd., an investment advisory client of Armistice Capital. The Master Fund is listed as having the right to receive dividends or sale proceeds on the reported shares.

Does Steven Boyd personally own the reported ADIL shares?

Steven Boyd is reported as a co-filer and managing member of Armistice Capital; the filing attributes shared voting and dispositive power to the reporting persons over 2,799,643 shares (9.99%). Footnotes state the Master Fund disclaims direct beneficial ownership under its agreement.

What voting and disposition powers are reported for the shares?

The filing reports 0 sole voting or dispositive power and 2,799,643 shares of shared voting power and shared dispositive power. These powers are reported as of 12/31/2025 and are based on issuer information.

Does the filing state any planned sale or transaction of ADIL shares?

No planned sale or transaction is described in the provided excerpt. The filing records current beneficial ownership and notes the Master Fund’s right to receive dividends or sale proceeds but does not disclose any disposition plans.
Adial Pharmaceuticals Inc

NASDAQ:ADIL

ADIL Rankings

ADIL Latest News

ADIL Latest SEC Filings

ADIL Stock Data

2.84M
1.09M
Biotechnology
Pharmaceutical Preparations
Link
United States
CHARLOTTESVILLE